372 related articles for article (PubMed ID: 18442408)
1. Potential role of miR-9 and miR-223 in recurrent ovarian cancer.
Laios A; O'Toole S; Flavin R; Martin C; Kelly L; Ring M; Finn SP; Barrett C; Loda M; Gleeson N; D'Arcy T; McGuinness E; Sheils O; Sheppard B; O' Leary J
Mol Cancer; 2008 Apr; 7():35. PubMed ID: 18442408
[TBL] [Abstract][Full Text] [Related]
2. miRNA profiling along tumour progression in ovarian carcinoma.
Vaksman O; Stavnes HT; Kaern J; Trope CG; Davidson B; Reich R
J Cell Mol Med; 2011 Jul; 15(7):1593-602. PubMed ID: 20716115
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract][Full Text] [Related]
4. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
[TBL] [Abstract][Full Text] [Related]
5. Novel miRNA genes deregulated by aberrant methylation in ovarian carcinoma are involved in metastasis.
Loginov VI; Pronina IV; Burdennyy AM; Filippova EA; Kazubskaya TP; Kushlinsky DN; Utkin DO; Khodyrev DS; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2018 Jul; 662():28-36. PubMed ID: 29631007
[TBL] [Abstract][Full Text] [Related]
6. Dicer, Drosha, and outcomes in patients with ovarian cancer.
Merritt WM; Lin YG; Han LY; Kamat AA; Spannuth WA; Schmandt R; Urbauer D; Pennacchio LA; Cheng JF; Nick AM; Deavers MT; Mourad-Zeidan A; Wang H; Mueller P; Lenburg ME; Gray JW; Mok S; Birrer MJ; Lopez-Berestein G; Coleman RL; Bar-Eli M; Sood AK
N Engl J Med; 2008 Dec; 359(25):2641-50. PubMed ID: 19092150
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
Benson EA; Skaar TC; Liu Y; Nephew KP; Matei D
PLoS One; 2015; 10(10):e0141279. PubMed ID: 26485143
[TBL] [Abstract][Full Text] [Related]
8. Primary and recurrent ovarian high-grade serous carcinomas display similar microRNA expression patterns relative to those of normal ovarian tissue.
Nam EJ; Kim S; Lee TS; Kim HJ; Lee JY; Kim SW; Kim JH; Kim YT
Oncotarget; 2016 Oct; 7(43):70524-70534. PubMed ID: 27655640
[TBL] [Abstract][Full Text] [Related]
9. miR-223 potentially targets SWI/SNF complex protein SMARCD1 in atypical proliferative serous tumor and high-grade ovarian serous carcinoma.
Arts FA; Keogh L; Smyth P; O'Toole S; Ta R; Gleeson N; O'Leary JJ; Flavin R; Sheils O
Hum Pathol; 2017 Dec; 70():98-104. PubMed ID: 29079174
[TBL] [Abstract][Full Text] [Related]
10. Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence.
Delfino KR; Rodriguez-Zas SL
PLoS One; 2013; 8(3):e58608. PubMed ID: 23554906
[TBL] [Abstract][Full Text] [Related]
11. miRNA expression profile changes in the peripheral blood of monozygotic discordant twins for epithelial ovarian carcinoma: potential new biomarkers for early diagnosis and prognosis of ovarian carcinoma.
Tuncer SB; Erdogan OS; Erciyas SK; Saral MA; Celik B; Odemis DA; Turkcan GK; Yazici H
J Ovarian Res; 2020 Aug; 13(1):99. PubMed ID: 32854743
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-150-5p promotes cell motility by inhibiting c-Myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
[TBL] [Abstract][Full Text] [Related]
13. miRNA-200a/c as potential biomarker in epithelial ovarian cancer (EOC): evidence based on miRNA meta-signature and clinical investigations.
Teng Y; Su X; Zhang X; Zhang Y; Li C; Niu W; Liu C; Qu K
Oncotarget; 2016 Dec; 7(49):81621-81633. PubMed ID: 27835595
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer.
Kandimalla R; Gao F; Matsuyama T; Ishikawa T; Uetake H; Takahashi N; Yamada Y; Becerra C; Kopetz S; Wang X; Goel A
Clin Cancer Res; 2018 Aug; 24(16):3867-3877. PubMed ID: 29514841
[No Abstract] [Full Text] [Related]
15. A microRNA survival signature (MiSS) for advanced ovarian cancer.
Shih KK; Qin LX; Tanner EJ; Zhou Q; Bisogna M; Dao F; Olvera N; Viale A; Barakat RR; Levine DA
Gynecol Oncol; 2011 Jun; 121(3):444-50. PubMed ID: 21354599
[TBL] [Abstract][Full Text] [Related]
16. Potential biomarker of circulating hsa-miR-1273g-3p level for detection of recurrent epithelial ovarian cancer.
Günel T; Gumusoglu E; Dogan B; Ertem FB; Hosseini MK; Cevik N; Senol T; Topuz S; Aydinli K
Arch Gynecol Obstet; 2018 Dec; 298(6):1173-1180. PubMed ID: 30264202
[TBL] [Abstract][Full Text] [Related]
17. Herpes virus microRNA expression and significance in serous ovarian cancer.
Pandya D; Mariani M; McHugh M; Andreoli M; Sieber S; He S; Dowell-Martino C; Fiedler P; Scambia G; Ferlini C
PLoS One; 2014; 9(12):e114750. PubMed ID: 25485872
[TBL] [Abstract][Full Text] [Related]
18. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression.
Tchernitsa O; Kasajima A; Schäfer R; Kuban RJ; Ungethüm U; Györffy B; Neumann U; Simon E; Weichert W; Ebert MP; Röcken C
J Pathol; 2010 Nov; 222(3):310-9. PubMed ID: 20726036
[TBL] [Abstract][Full Text] [Related]
19. Differential MicroRNA Expression Profiles in Primary and Recurrent Epithelial Ovarian Cancer.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Lee YS; Cho YL
Anticancer Res; 2015 May; 35(5):2611-7. PubMed ID: 25964536
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
